Eli Lilly is betting big on genetic medicines, inking a deal with Ascidian Therapeutics worth up to $1.9 billion to develop treatments for inherited kidney diseases.
The big picture: Lilly is betting that rewriting RNA may succeed where gene therapy and gene editing have struggled.
